本帖最后由 老马 于 2012-1-13 21:20 编辑 : J& q, p/ g! Z# u0 d" J
) M$ g" l& ]" N3 C
爱必妥和阿瓦斯丁的比较 m L8 p- K) w2 I8 h: Q8 E
% |4 w1 d3 A" r$ P; N; M4 r# P4 _( w# }+ G
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/% Q4 f: A: J- l' s' L/ Z# t
# X' X8 r Z" l3 ~$ N" A$ t+ `
4 x; j2 b8 A- W- N I- }9 Nhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
/ d7 B3 t' g6 [==================================================" [. }( X4 x3 \ N
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). m/ M2 e7 W' q6 ?7 B
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point." b+ t# R2 a8 ], h; j$ I: P) `& c
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.5 N9 G* T$ t5 v, E1 g V
|
显身卡
